# Study of Docetaxel and Gemcitabine in Metastatic Esophageal Squamous Cell Cancer

> **NCT01469598** · PHASE2 · COMPLETED · sponsor: **Samsung Medical Center** · enrollment: 24 (actual)

## Conditions studied

- Metastatic Carcinoma
- Recurrent Esophageal Squamous Cell Carcinoma

## Interventions

- **DRUG:** Gemcitabine/Docetaxel

## Key facts

- **NCT ID:** NCT01469598
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-08
- **Primary completion:** 2014-02
- **Final completion:** 2015-01
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2015-12-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01469598

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01469598, "Study of Docetaxel and Gemcitabine in Metastatic Esophageal Squamous Cell Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01469598. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*